Current Issue

Sponsored
Keywords

Bioethics - Related Content

BioPerspectives: Avoiding “Incidental” Damages
Presidential panel, ACMG, and experts struggle with what patients should learn, and how.
Point of View: Anti-GE Activism: Will It Ever End?
What Is Motivating the Anti-Genetic Engineering Foods Movement?
Insight & Intelligence™: Is It OK to Take DNA from Arrested Suspects?
Supreme Court Weighs Constitutionality of Collecting Samples Absent a Conviction
BioPerspectives: Anti-Genetic Engineering Activism: Why the Bastards Never Quit
Dr. Henry I. Miller is back to talk about what he feels motivates the anti-GE foods movement.
Legal Affairs: Commission Takes Stab at WGS Policy
Group Focuses on Data-Sharing and Privacy Concerns Inherent with Whole-Genome Sequencing

Your Genes, Your Choice?
May 9, 2013
Critics say the American College of Medical Genetics and Genomics’ recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy.
DNA Collection v. DNA Privacy
February 27, 2013
Supreme Court weighs constitutionality of taking samples from arrested suspects absent a conviction.
Arrivederci, GINA
February 4, 2013
New rules on protecting genetic privacy are under way, as study rekindles debate over sharing vs. protecting data.
Top 10 Biggest Biopharma Marketing Fines
January 29, 2013
Find out which companies have made false claims about their products—and are paying the most for it now.
One Small Step, No Giant Leap for Privacy
October 18, 2012
Privacy and Progress in Whole-Genome Sequencing report lacks implementation framework.

Presidential Commission’s Report on Synthetic Biology
Drew Endy is an assistant professor of bioengineering at Stanford University. He earned a BS and MS in civil and environmental engineering, respectively, from Lehigh University and a Ph.D. in biochemical engineering from Dartmouth College.
CLINICAL TRIAL ETHICS IN THE DEVELOPING WORLD
- Jonathan Kimmelman, Ph.D., Assistant Professor in the Biomedical Ethics Unit/Social Studies of Medicine Department, McGill University
IMPLICATIONS OF GINA FOR THE BIOTECH AND PHARMA INDUSTRIES
- Interview with Sharon Terry, President and CEO of the Genetic Alliance